08 Apr. 2019
PRESS RELEASE - NEW CDO AT BIOVERSYS - DR. GLENN DALE
BioVersys is pleased to announce the appointment of Dr. Glenn Dale as Chief Development Officer as of February 1st, 2019.
08 Apr. 2019
FRESH FUNDS TO FUEL THE FIGHT AGAINST DRUG-RESISTANT BACTERIA
BioVersys together with BioSystems Technology and Voxcan announced funding - € 840,000 over a 3-year period - by Eurostars for IMPACT2, a new translat...
10 Apr. 2019
BIOSYSTEMS TECHNOLOGY, BIOVERSYS AND VOXCAN ANNOUNCE FUNDING BY EUROSTARS
BioSystems Technology, BioVersys and Voxcan announce funding for a total of about € 840’000, by Eurostars over a 3-year period for IMPACT2, a break-th...
Recent Media Feeds
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
